X

Trial Profile

A Phase 2 trial to investigate low-dose psilocybin's efficacy in treating generalized anxiety disorder

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 24 Mar 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Psilocybin (Primary)
Indications Generalised anxiety disorder
Focus Therapeutic Use
Sponsors Diamond Therapeutics

Most Recent Events

21 Mar 2023 According to Diamond Therapeutics media release, Phase 2 study will be conducted in Canada on a take-at-home basis and has received Health Canada approval.
07 Dec 2022 According to Diamond Therapeutics media release, this Phase II study will be conducted in Canada under Health Canada regulations
24 Aug 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com